A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.

Researchers identified AlCas12a, a compact, versatile enzyme that improves CRISPR gene editing and enables faster molecular ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

And, if all goes well, over the next five years as well.

US biotech start-up Aurora Therapeutics has launched with $16 million in seed funding from Menlo Ventures, aiming to turn one-off CRISPR gene-editing successes into a scalable model for rare diseases.

A bacterial defense system called SPARDA employs kamikaze-like tactics to protect cells and could be useful in future ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now. Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.65, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. On the other hand, the ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on Wednesday, adding 9.6 percent to close at $60.08 apiece, tracking the rally in ...